PRECISESADS is an EU project formed by 21 academic, 2 SMEs and 5 industrial partners from 12 countries spread right across Europe, planned for 5 years with a budget of €22.7 million, €9.9 million of which comes from the European Commission’s Seventh Framework Program for Research (FP7, Innovative Medicines Initiative Joint Undertaking, GA n° 115565), and €9.8 million of which comes from contributions by the pharmaceutical companies participating in the project.
About PRECISESADS
- Home
- About PRECISESADS
PRECISESADS brings together industry experience with academic and clinical expertise in the fields of genetics, metabolomics, mass spectrometry, rheumatology, and autoimmunology. The project will provide an advantage for the European pharmaceutical industry through the unique possibility of sharing new and existing data and findings on an unprecedented scale for these diseases. The expertise of the pharmaceutical industry is essential, as they have important knowledge of prior failures in this disease area and understand the urgent need to overcome the problem of the current classification of patients. By pooling existing data and using cutting-edge technologies, the project will help to pave the way for more effective and earlier treatment of these debilitating and dangerous autoimmune diseases. The research being undertaken has always been seen as necessary but sufficient funding and a collaborative model has only now become possible through IMI. This is a unique research project that will directly benefit from advances in technology and will ultimately deliver results at the patient’s bedside.
The goal of this project
The goal of this project is the use of the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therapeutic agents that are being developed for one disease but cannot be applied to another due to current clinical classifications.
We are investigating individuals with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren’s syndrome (Sjs), rheumatoid arthritis (RA), primary antiphospholipid syndrome (PAPS) and mixed connective tissue disease (MCTD), jointly as systemic autoimmune diseases (SADs).
Results
Results will be widely shared to deliver a new molecular taxonomy of systemic autoimmune diseases that can be directly accessed by physicians, patients, regulators and drug developers to help define, refine and discover better treatments for SADs. In order to achieve this, we are informing punctually and on a regular basis on the project implementation and results, and involve stakeholders from Europe in its activities in order to broaden the projects’ impact and increase opportunities for cooperation.
For any questions or suggestions
